Testing a higher dose of an experimental CMV vaccine in healthy adults
Part of Immune system & allergy, Infections clinical trials.
This study tests a higher dose of an experimental vaccine (VIR-1388) that may help prevent infection with cytomegalovirus (CMV), a common virus that can be harmful to people with weakened immune systems and to unborn babies. The vaccine is given to healthy adults who already have CMV to see if it is safe and produces a good immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You have had a CMV infection in the past (a simple blood test can confirm this).
- You are in good general health, with no major medical conditions like diabetes, autoimmune diseases, or bleeding disorders.
- You have not taken certain antiviral medications (like acyclovir or ganciclovir) within the past 30 days.
- You have not received an experimental vaccine in the past year (some exceptions may apply).
- You are willing to use condoms during the study and avoid donating blood, sperm, or tissues until the study ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
This trial tests an experimental vaccine called VIR-1778 that may help protect against infections caused by two viruses: cytomegalovirus (CMV) and tuberculosis (TB). The study looks at whether the vaccine is safe and how well it works in healthy adults.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
This study tests an experimental medication in healthy volunteers to see how it is processed by the body and whether it is safe. You may not receive direct benefit, but your participation helps find better treatments for people with HIV.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Hear when a new Cytomegalovirus (CMV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.